Texas' 58th Judicial District Court in Beaumont will host a Risperdal trial this month. Beginning June 12, 2016, Jacoby Moore vs. Ortho-McNeil-Janssen Pharmaceuticals, Inc., et al. will be presented to the first Texas judge

Many people assume that oversight of drug development and marketing by FDA is adequate to insure  public protection from dangerous products, and that an FDA-approved product's benefits outweigh its risks. Professional evaluations of FDA

A Philadelphia jury ordered Johnson & Johnson in Feb. 2015 to pay $2.5 million to an Alabama man who developed  46 DD breasts as a teenager after taking Risperdal. The jury agreed with the

Important Risperdal lawsuit documents could be sealed if the manufacturer of the drug has its way with the Philadelphia County Court of Common Pleas. One of Johnson & Johnson’s latest moves in the company’s

The FDA reported in a November news release that Janssen Pharmaceuticals, Inc. would plead guilty and pay more than $1.6 billion to resolve charges the company misbranded Risperdal and filed false claims for its

The FDA reported in a news release last month that Janssen Pharmaceuticals, Inc. would plead guilty and pay more than $1.6 billion to resolve charges the company misbranded Risperdal and filed false claims for

Johnson & Johnson has agreed to pay $2.2 Billion and plead guilty to a misdemeanor in a deal to settle a U.S. Department of Justice investigation into the marketing of Risperdal and other drugs.

Risperdal (risperidone) increases the risk of developing breasts and hyperprolactemia. Recently, Risperdal maker Janssen,  a Johnson & Johnson subsidiary, has been blamed for its failure to inform the public that young males or boys taking

Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, received a $1.1 billion fine by an Arkansas judge for allegedly lowering the profile of the risk of certain side effects in off-label uses and hiding